BioPharma Terug naar discussie overzicht

INSM - Insmed - Deel 15

1. [verwijderd] 30 maart 2007 23:08

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis.
   
   * Liu B,
   * Lee KW,
   * Anzo M,
   * Zhang B,
   * Zi X,
   * Tao Y,
   * Shiry L,
   * Pollak M,
   * Lin S,
   * Cohen P.
   
   (...)Together, these studies provide the first evidence that IGFBP-3 has direct, IGF-independent inhibitory effects on angiogenesis providing an additional mechanism by which it exerts its tumor suppressive effects and further supporting its development for clinical use in the therapy of patients with prostate cancer.Oncogene (2007) 26, 1811-1819. doi:10.1038/sj.onc.1209977;
   tinyurl.com/2egn94
   
   Shiry is INSMED
   Pollak presenteert ook op ENDO meeting 2007!
   
   IGFs & Cancer
   
   Tuesday, June 5, 2007
   9:30 AM-11:00 AM
   
   Chair: Terri Wood, New Jersey Med Sch/Univ of Med & Dent of New Jersey
   
   *
   
   Inhibition of Oncogenic Actions of IGF-IR with PPP
   Olle Larsson, Karolinska Inst (Sweden)
   *
   
   IGF & IGFBP in Epithelial Tumors
   Michael Pollack, Lady Davis Res Inst, McGill Univ (Canada)
   *
   
   Estrogen, IGF-1 & Cancer
   Eva Surmacz, Temple Univ
   www.endo-society.org/endo/program/det...
   
   ...Ook een poster van Kenneth Attie (INSMED)
   
   Acute and Chronic Treatment of Severe IGF-I Deficiency with Once Daily rhIGF-I/rhIGFBP-3 Results in Parallel Increases in IGF-I and IGFBP-3 and Normal Free IGF-I Levels.
   
   Geluk, F.
   
   
2. [verwijderd] 31 maart 2007 17:29

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Mooi stukje Frederik.
   
   Hier nog wat meer van iHub omtrent MMD:
   
   MMD poster May 4, 2007.
   
   "SC02.004 Effects of IPLEX™ in
   Myotonic Dystrophy Type 1 (DM1)
   Chad R. Heatwole, William Martens,
   Christine Quinn, James Hilbert,
   Shree Pandya, Carlayne Jackson,
   Charles Thornton, Richard Moxley"
   
   am.aan.com/scientific/neuroscience.cfm
   
   "The embargo for all abstracts to be presented at the 59th Annual Meeting is in effect until the date and time of the presentation unless otherwise noted on the abstract and/or press release. If there are questions, please contact the AAN media and public relations team."
   
   The abstract is available if you look for it. I will not post it here because of above restriction. The study is very small with only three completed and five in the process. The results were effective in multiple areas, safe and well tolerated. The decline eight weeks after treatment stoped were significant in all areas where improvement was noted. The largest positive I got out of this abstract is the positive results that will be more important for the HARS study.
   
   May 4,2007 we will receive our long awaited MMD results but since we already have them?
   
   April 30, 2007 discussion.
   
   "Discussion Session – Therapeutic Developments in Muscular Dystrophy // 4:00 – 6:00 p.m. // Room 100
   4:00 p.m.–4:25 p.m. First FDA Approved Treatment for Muscle Disease Priya Kishnani, MD, Durham, NC
   4:25 p.m.–4:50 p.m. Stop Codon Therapy for Muscular Dystrophy Richard Finkel, MD, Philadelphia, PA
   4:50 p.m.–5:15 p.m. Non-viral Gene Therapy and Other Approaches Robert H. Brown, MD, D.Phil, Charlestown, MA
   5:15 p.m.–5:40 p.m. Myostatin Blockade, One Way or Another Kathryn Wagner, MD, PhD, Baltimore, MD
   5:40 p.m.–6:00 p.m. Treatment for Myotonic Dystrophy: What If? Charles Thornton, MD, FAAN, Rochester, NY"
   
   Note Charles Thornton in both presentations.
   
   am.aan.com/scientific/pdf/INS_Muscula...
   
   "Coordinators: Charles A. Thornton, MD, FAAN, and Kathryn R. Wagner, MD, PhD"
   
   Rod
   
   mvg, E.
3. [verwijderd] 31 maart 2007 18:13

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Geweldig! Een vervolg op:
   
   1: Muscle Nerve. 2007 Jan 17;35(4):479-485 [Epub ahead of print]Click here to read Links
   Severity, type, and distribution of myotonic discharges are different in type 1 and type 2 myotonic dystrophy.
   
   * Logigian EL,
   * Ciafaloni E,
   * Quinn LC,
   * Dilek N,
   * Pandya S,
   * Moxley RT 3rd,
   * Thornton CA.
   
   Neuromuscular Division, Department of Neurology, Box 673, 601 Elmwood Avenue, University of Rochester Medical Center, Rochester, New York 14642, USA.
   
   To characterize and compare electrical myotonia in myotonic dystrophy type 1 (DM1) and type 2 (DM2), 16 patients with genetically confirmed DM1 and 17 patients with DM2 underwent standardized concentric needle electromyography of deltoid, biceps, extensor digitorum communis, first dorsal interosseous, tensor fascia lata (TFL), vastus lateralis (VL), tibialis anterior, and thoracic paraspinal muscles. Eight needle insertions per muscle were made by electromyographers blinded to DM type who recorded the presence and type of myotonia (e.g., classic waxing-waning or less specific waning discharges). Manual muscle testing was performed by a physical therapist. Overall, myotonia was more elicitable in DM1 than DM2; only in VL and TFL was myotonia more elicitable in DM2 than DM1. The major type of myotonia was waxing-waning in DM1, and waning in DM2. Four DM2 (24%), but no DM1 patients had only waning myotonia. In the arms, myotonia was distally predominant in both DM1 and DM2. In the legs, it was distally predominant in DM1, but both proximal and distal in DM2. The severity of myotonia was positively correlated with muscle weakness and with the presence of waxing and waning discharges in DM1, but with neither in DM2. Thus, myotonia is qualitatively and quantitatively different in DM1 than DM2. Except for proximal leg muscles, myotonia is more evocable in DM1 than DM2. It tends to be waxing-waning in DM1 but waning in DM2, thus making electrodiagnosis of DM2 more challenging. Its severity correlates with muscle weakness and the presence of waxing-waning discharges in DM1 but not DM2. Muscle Nerve, 2007.
   tinyurl.com/3a2tea
   
   Geluk, F.
4. [verwijderd] 1 april 2007 00:56

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   There we go!!!
   
   Effects of IPLEX in Myotonic Dystrophy Type 1 (DM1)
   
   Chad R. Heatwole, William Martens, Christine Quinn, James Hilbert, Shree Pandya, Carlayne Jackson, San Antonio, TX, Charles Thornton, Richard Moxley, Rochester, NY
   
   OBJECTIVE: To evaluate the safety, tolerability, and efficacy of human insulin growth factor (IGF) complexed with IGF binding protein 3 (IPLEX TM, Insmed Inc.) in improving lean body mass, muscle strength, functionality, and laboratory profiles in DM1. BACKGROUND: DM1 patients suffer from progressive muscle wasting, weakness, and disability. To date there is no cure for DM1 or these symptoms. Some hypothesize that decreased intracellular signaling by IGF-1 contributes to weakness and atrophy. A prior study of recombinant IGF-1 in DM1 patients improved insulin action and strength, although side effects occurred. Compared to recombinant IGF-1, IPLEX TM is a longer acting preparation with fewer side effects. DESIGN/METHODS: Three DM1 patients completed a trial of 24 weeks of IPLEX TM. Dosages were set at 0.5mg/kg/day for eight weeks followed by a titration to 1.0mg/kg/day. Each patient was monitored closely and periodically admitted for safety monitoring, functional abilities, laboratory testing, DEXA evaluation, and manual muscle testing (MMT) of 26 separate muscle groups. RESULTS: These patients tolerated IPLEX TM without significant adverse side effects. After 24 weeks of treatment, patients demonstrated increases in lean body mass: 1.1 kg (2.5%); average MMT: 0.1 points per muscle group (2.2%); and testosterone levels: 280 ng/dl (58%) with decreases in body fat: -0.7 kg (-2.8%); LDL: -43 mg/dl (-35%); and triglycerides: -6.3 mg/dl (-5.5%). Eight weeks after discontinuing therapy, patients had reductions in lean body mass: -1.8 kg (-3.6%); average MMT: -.38 points per muscle group (-8.8%); and testosterone levels: -333 ng/dl (-43%) with increases in body fat: 0.5 kg (1.9%); triglyceride levels: 44 mg/dl (44%); and LDL: 16 mg/dl (20%). Five additional patients are currently enrolled in this study. Their data will be added to the results once they have completed the above study protocol. CONCLUSIONS/RELEVANCE: Preliminary data suggest that IPLEX TM is safe and well tolerated in DM1. Supported by: NIH grant U54NS48843-03 and Insmed Inc.
   Category - Muscle Disease/Neuromuscular Junction
   SubCategory - Therapeutics
   
   Friday, May 4, 2007 11:00 AM
   
   Poster Session: Future of Neuroscience Conference: Therapy of Genetic Disorders (1:00 PM-5:00 PM)
   
   The embargo for all abstracts to be presented at the 59th Annual Meeting is in effect until the date and time of the presentation unless otherwise noted on the abstract and/or press release. If there are questions, please contact the AAN media and public relations team.
   www.abstracts2view.com/aan2007boston/...
   
   Geluk, F.!
5. [verwijderd] 1 april 2007 01:20

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   Frederik C schreef:

   There we go!!!
   
   Effects of IPLEX in Myotonic Dystrophy Type 1 (DM1)
   
   Chad R. Heatwole, William Martens, Christine Quinn, James Hilbert, Shree Pandya, Carlayne Jackson, San Antonio, TX, Charles Thornton, Richard Moxley, Rochester, NY
   
   OBJECTIVE: To evaluate the safety, tolerability, and efficacy of human insulin growth factor (IGF) complexed with IGF binding protein 3 (IPLEX TM, Insmed Inc.) in improving lean body mass, muscle strength, functionality, and laboratory profiles in DM1. BACKGROUND: DM1 patients suffer from progressive muscle wasting, weakness, and disability. To date there is no cure for DM1 or these symptoms. Some hypothesize that decreased intracellular signaling by IGF-1 contributes to weakness and atrophy. A prior study of recombinant IGF-1 in DM1 patients improved insulin action and strength, although side effects occurred. Compared to recombinant IGF-1, IPLEX TM is a longer acting preparation with fewer side effects. DESIGN/METHODS: Three DM1 patients completed a trial of 24 weeks of IPLEX TM. Dosages were set at 0.5mg/kg/day for eight weeks followed by a titration to 1.0mg/kg/day. Each patient was monitored closely and periodically admitted for safety monitoring, functional abilities, laboratory testing, DEXA evaluation, and manual muscle testing (MMT) of 26 separate muscle groups. RESULTS: These patients tolerated IPLEX TM without significant adverse side effects. After 24 weeks of treatment, patients demonstrated increases in lean body mass: 1.1 kg (2.5%); average MMT: 0.1 points per muscle group (2.2%); and testosterone levels: 280 ng/dl (58%) with decreases in body fat: -0.7 kg (-2.8%); LDL: -43 mg/dl (-35%); and triglycerides: -6.3 mg/dl (-5.5%). Eight weeks after discontinuing therapy, patients had reductions in lean body mass: -1.8 kg (-3.6%); average MMT: -.38 points per muscle group (-8.8%); and testosterone levels: -333 ng/dl (-43%) with increases in body fat: 0.5 kg (1.9%); triglyceride levels: 44 mg/dl (44%); and LDL: 16 mg/dl (20%). Five additional patients are currently enrolled in this study. Their data will be added to the results once they have completed the above study protocol. CONCLUSIONS/RELEVANCE: Preliminary data suggest that IPLEX TM is safe and well tolerated in DM1. Supported by: NIH grant U54NS48843-03 and Insmed Inc.
   Category - Muscle Disease/Neuromuscular Junction
   SubCategory - Therapeutics
   
   Friday, May 4, 2007 11:00 AM
   
   Poster Session: Future of Neuroscience Conference: Therapy of Genetic Disorders (1:00 PM-5:00 PM)
   
   The embargo for all abstracts to be presented at the 59th Annual Meeting is in effect until the date and time of the presentation unless otherwise noted on the abstract and/or press release. If there are questions, please contact the AAN media and public relations team.
   www.abstracts2view.com/aan2007boston/...
   
   Geluk, F.!
   

   In bovenstaand kader ook interessant:
   www.parentprojectmd.org/site/DocServe...
   
   Geluk, F.
6. [verwijderd] 3 april 2007 15:40

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Hoe hoog is vandaaag geopend?
7. [verwijderd] 3 april 2007 15:45

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Laatste 0,91 15:43 100
   +/- -0,02 -2,15%
   Open 0,91 15:39
   Slot 0,93 2/4
   Hoog 0,92 15:41
   Laag 0,89 15:39
   Volume 15.458
   
   vr gr willem
8. [verwijderd] 3 april 2007 15:54

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   bedankt
   
   Nico
9. ludwig mack 4 april 2007 16:18

   auteur info

   • ludwig mack

     Lid sinds: 30 jan 2004

     Laatste bezoek: 05 feb 2025

   • Aanbevelingen

     Ontvangen: 412

     Gegeven: 29

   •    Aantal posts: 8.675

   Laatste 0,92
   Laatste volume 100
   Tijd 16:16
   +/- 0,01 1,03%
   Volume 104.853
   
   Bied
   Biedvolume
   Laat
   Laatvolume
   
   Slot 0,91 3/4
   Open 0,90 15:30
   Hoog 0,94 15:51
   Laag 0,90 15:30
   
   
10. [verwijderd] 4 april 2007 16:29

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    He'll be replaced by Philip Young, who was chief business officer at Insmed
    
    Osteologix loses CEO
    Tuesday April 3, 6:10 pm ET
    
    Osteologix Inc. said Tuesday that its CEO and president, Charles Casamento, quit, effective immediately.
    He'll be replaced by Philip Young, who was chief business officer at Insmed Inc.
    
    San Francisco-based Osteologix (OTCBB: OLGX - News) said only that Casamento quit to "pursue other opportunities." He'll stay on the company's board but won't stand for re-election at the next annual meeting. The company will also keep paying him as a consultant for three months.
    
    Casamento became CEO of Osteologix, which seeks treatments for bone diseases and for uses in women's health, in October 2004.
    
    Published April 3, 2007 by San Francisco Business Times
    
    biz.yahoo.com/bizj/070403/1441785.htm...
12. [verwijderd] 4 april 2007 22:05

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    ** Serious attempt to paint it down.. bought 3k @ 0,86 (Not rated) 8 second(s) ago Tight range the entire day between 0,90- 0,94
    with solid buyblock catching all on 0,90
    
    By: read_this_n0w Send PM Profile Ignore Add To Favorites
    Attempt to paint it down.... bought 3k@ 0,8602 at the close~!!!
    
    - BOT 3200
    INSM false Stock INSM (NMS) 0.860075 USD ISLAND 20070404 22:00:33 MktDepth
    BOT 800 INSM false Stock INSM (NMS) 0.86 USD ISLAND 20070404 22:00:33 00011f47.455f8b8c.01.01 MktDepth
    BOT 2400 INSM false Stock INSM (NMS) 0.8601 USD ISLAND 20070404 22:00:33 00011f47.455f8b8d.01.01 MktDepth
    
    ---------------------------------
    Todays volume distribution
    
    335.815 stuks à 0,90 38,7%
    385.091 stuks à 0,91 44,8%
    91.040 stuks à 0,92 10,7%
    48.768 stuks à 0,93 5,8%
    200 stuks à 0,94 0,0%
    
    Sentiment : Buy
    
    
13. [verwijderd] 4 april 2007 22:28

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Graag rapporteren bij de SEC , zal niet veel uitmaken
    maar met INSM op de REG SHO wel gedaan
    
    ---------------------------
    
    to: enforcement@sec.gov
    topic: Attempt to pain the close at INSM, while on REG sho list as well!!!
    
    Would like to report attempt to paint the close today in a stock that has a 90mln market cap
    Which recently got on the REG SHO list (with NO removal so far)
    
    And now there are attempts to paint the close..
    in conjunction with bashers working msg boards...
    
    last time i checked, such actions were illegal
    
    Below the msg i wrote on a msg board...
    I was able to buy 3.000 shares @0,8602 allmost simultaneous on the at 22:00:33 through ISLAND, while the ENTIRE day range was 0,90-0,96
    with a regular bid of 0,90 at 22:00 hours... and a regular 22:00:00 closing price of 0,91
    
    How much clearer can an attempt to paint the close be??
    
    Sincerely hope the SEC will prevent the active marketmakers from allowing them to make such moves, especially since INSM recently showed
    up at the REG SHO list.... which should not be there to help out short sellers who miscalculated retail stubborness not to sell!!!
    
    last time i checked attempts to paint the close WERE illegal
    
    With regards,
    
    Included is todays volume range
    
    ---------------------------------------
    
    Als je je verveelt, dan mailen graag
    pas maar aan aan je eigen verhaal.. of vertel over mijn aankoop of gebruik delen van mijn email en mijn aankoopgegevens
    
    je weet het nooit met insm op de REG SHO lijst
    !!!
14. [verwijderd] 5 april 2007 16:30

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Het lijkt wel lente: ++ 4 cents (0,94) en klimmend.
    Maar wel laag volume.
    
    P.
15. spyfly 5 april 2007 17:09

    auteur info

    • spyfly

      Lid sinds: 28 jan 2002

      Laatste bezoek: 29 mei 2024

    • Aanbevelingen

      Ontvangen: 3

      Gegeven: 11

    •    Aantal posts: 476

    INSM 0.96 +0.06 (6.56%)
    
    zowaar!
16. [verwijderd] 5 april 2007 21:41

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    ++7,9%
    
    1.200.000
    
    P.
17. ludwig mack 5 april 2007 22:46

    auteur info

    • ludwig mack

      Lid sinds: 30 jan 2004

      Laatste bezoek: 05 feb 2025

    • Aanbevelingen

      Ontvangen: 412

      Gegeven: 29

    •    Aantal posts: 8.675

    quote:

    crackedtooth schreef:

    Graag rapporteren bij de SEC , zal niet veel uitmaken
    maar met INSM op de REG SHO wel gedaan
    
    ---------------------------
    
    to: enforcement@sec.gov
    topic: Attempt to pain the close at INSM, while on REG sho list as well!!!
    
    Would like to report attempt to paint the close today in a stock that has a 90mln market cap
    Which recently got on the REG SHO list (with NO removal so far)
    
    And now there are attempts to paint the close..
    in conjunction with bashers working msg boards...
    
    last time i checked, such actions were illegal
    
    Below the msg i wrote on a msg board...
    I was able to buy 3.000 shares @0,8602 allmost simultaneous on the at 22:00:33 through ISLAND, while the ENTIRE day range was 0,90-0,96
    with a regular bid of 0,90 at 22:00 hours... and a regular 22:00:00 closing price of 0,91
    
    How much clearer can an attempt to paint the close be??
    
    Sincerely hope the SEC will prevent the active marketmakers from allowing them to make such moves, especially since INSM recently showed
    up at the REG SHO list.... which should not be there to help out short sellers who miscalculated retail stubborness not to sell!!!
    
    last time i checked attempts to paint the close WERE illegal
    
    With regards,
    
    Included is todays volume range
    
    ---------------------------------------
    
    Als je je verveelt, dan mailen graag
    pas maar aan aan je eigen verhaal.. of vertel over mijn aankoop of gebruik delen van mijn email en mijn aankoopgegevens
    
    je weet het nooit met insm op de REG SHO lijst
    !!!
    

    waarom zo'n populair woordgebruik met "painten", moest een paar keer lezen wat je bedoelt, als het anders kan en vraag me af of je niet met duidelijkere stelling / klacht beter af zou zijn bij de instaties. er blijkt wel uit dat je je terecht ergert.
    gr
18. [verwijderd] 6 april 2007 06:36

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    painten= wat het is, normaal US taalgebruik
    
    maargoed..
    
    lijkt op reversal patroon.. kijken of maandag bevestigd word
19. [verwijderd] 9 april 2007 18:10

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Ik heb bijgekocht op 0,94 en 0,93, vooral gezien beweging vrijdag
    
    low volume, chaikin money flow lijkt positief te draaien
    
    level2 attachment

    Bijlage:
20. [verwijderd] 9 april 2007 18:16

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    crackedtooth schreef:

    painten= wat het is, normaal US taalgebruik
    
    maargoed..
    
    lijkt op reversal patroon.. kijken of maandag bevestigd word
    

    De bevestiging lijkt er nog niet te komen.
21. [verwijderd] 9 april 2007 19:24

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    crackedtooth schreef:

    Ik heb bijgekocht op 0,94 en 0,93, vooral gezien beweging vrijdag
    
    low volume, chaikin money flow lijkt positief te draaien
    
    level2 attachment
    

    ik verwacht binnenkort weer 1,04 getest te zien